(0.23%) 5 143.50 points
(0.14%) 38 494 points
(0.37%) 17 911 points
(-0.61%) $83.34
(1.98%) $1.961
(-0.13%) $2 344.10
(-0.07%) $27.52
(2.86%) $948.50
(-0.02%) $0.934
(-0.03%) $11.02
(-0.23%) $0.799
(1.90%) $93.61
Live Chart Being Loaded With Signals
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...
Stats | |
---|---|
本日の出来高 | 1.01M |
平均出来高 | 4.70M |
時価総額 | 26.84B |
EPS | €0 ( 2024-03-04 ) |
次の収益日 | ( €2.32 ) 2024-05-14 |
Last Dividend | €2.40 ( 2023-05-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | -9.14 |
ATR14 | €0.0150 (0.05%) |
ボリューム 相関
Bayer AG 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Bayer AG 相関 - 通貨/商品
Bayer AG 財務諸表
Annual | 2023 |
収益: | €47.64B |
総利益: | €27.89B (58.54 %) |
EPS: | €-2.99 |
FY | 2023 |
収益: | €47.64B |
総利益: | €27.89B (58.54 %) |
EPS: | €-2.99 |
FY | 2022 |
収益: | €50.74B |
総利益: | €30.87B (60.84 %) |
EPS: | €4.22 |
FY | 2021 |
収益: | €44.08B |
総利益: | €27.27B (61.85 %) |
EPS: | €1.018 |
Financial Reports:
No articles found.
Bayer AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€2.40 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €1.279 | 2000-05-02 |
Last Dividend | €2.40 | 2023-05-02 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | €43.29 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.56 | -- |
Div. Sustainability Score | 3.23 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 2.71 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
UBK.DE | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
DWS.DE | Ex Dividend Knight | 2023-06-16 | Annually | 0 | 0.00% | |
NEM.DE | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
AAG.DE | Ex Dividend Junior | 2023-06-16 | Sporadic | 0 | 0.00% | |
XTP.F | Ex Dividend Junior | 2023-05-12 | Sporadic | 0 | 0.00% | |
FRE.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
PHI1.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
AWC.DE | Ex Dividend Junior | 2023-08-07 | Quarterly | 0 | 0.00% | |
HRPK.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
SGF.DE | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0617 | 1.500 | -1.235 | -1.852 | [0 - 0.5] |
returnOnAssetsTTM | -0.0238 | 1.200 | -0.795 | -0.954 | [0 - 0.3] |
returnOnEquityTTM | -0.0816 | 1.500 | -2.02 | -3.03 | [0.1 - 1] |
payoutRatioTTM | -0.809 | -1.000 | -8.09 | 8.09 | [0 - 1] |
currentRatioTTM | 1.259 | 0.800 | 8.70 | 6.96 | [1 - 3] |
quickRatioTTM | 0.784 | 0.800 | -0.0946 | -0.0757 | [0.8 - 2.5] |
cashRatioTTM | 0.201 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.355 | -1.500 | 4.08 | -6.11 | [0 - 0.6] |
interestCoverageTTM | 0.595 | 1.000 | -0.891 | -0.891 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 8.97 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.332 | -1.500 | 4.67 | -7.01 | [0 - 2.5] |
grossProfitMarginTTM | 0.585 | 1.000 | 3.58 | 3.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0333 | 1.000 | -1.333 | -1.333 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.109 | 1.000 | -0.507 | -0.507 | [0.2 - 2] |
assetTurnoverTTM | 0.386 | 0.800 | -0.759 | -0.607 | [0.5 - 2] |
Total Score | 3.23 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.15 | 1.000 | -1.026 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0816 | 2.50 | -1.297 | -3.03 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 9.32 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 9.16 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.809 | 1.500 | -8.09 | 8.09 | [0 - 1] |
pegRatioTTM | 0.117 | 1.500 | -2.55 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.100 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。